Table 1.

Baseline patient, cancer, immune status, and anti-cancer therapy characteristics

		N=87
Age (years)	median (range)	12 (0–24)
Sex, n (%)
	Male	48 (55)
	Female	39 (45)
Ethnicity, n (%)
	Hispanic	64 (74)
	Non-Hispanic	23 (26)
Weight status
	Overweight	14 (16)
	Obese	28 (32)
	Lean	45 (52)
Cancer, n (%)
	Hem n (%)	63 (72)
	ALL	53
	AML	2
	Hodgkin	2
	NHL	2
	Other	4
	Non-Hem n (%)	24 (28)
	Brain	3
	Sarcoma	7
	Neuroblastoma	8
	Wilms	3
	Retinoblastoma	1
	Other	2
Therapy, n (%)
	Chemo	64 (74)
	HSCT	12 (14)
	CAR	7 (8)
	CAR & HSCT	4 (4)
Chemotherapy intensity (n=64) a
	Intense	29
	Non-intense	35
HSCT type (n=16)
	Allogeneic	10
	Autologous	6
Days since therapy, median(range) b
	HSCT	305 (−39–3939)
	CAR	629 (21–2142)
Steroids c , n (%)		18 (21)
Anthracyclines, n (%)		65 (75)
Neutropenia d , n (%)		14 (16)
Lymphopenia e , n (%)		35 (40)
Any Comorbidity, n (%)		51 (59)
	Neurological	14
	Cardiac	9
	Pulmonary	5
	Renal	4
	Endocrine	4
	Infectionf	8
	Gastrointestinal	10
	Other	19
GVHD
	Acute	1
	Chronic	2
Immune status (allo-HSCT, n=9) g
	Lymphopenia	0
	Neutropenia	0
	CD4<200	0
Immune status (CAR, n=8) g
	Lymphopenia	3
	Neutropenia	0
	CD4<200	2
	B-cell aplasia	7

^aIntense: patients in the midst of a highly myelosuppressive phase of chemotherapy at the time of COVID-19 infection.

^bDays: time interval between the date of last anti-cancer therapy (HSCT or CAR) and the date of the first positive COVID-19 PCR.

^cReceived systemic steroids (not including steroids given as part of COVID-19 management) within two weeks prior to the date of COVID-19 diagnosis.

^dAbsolute neutrophil count <500.

^eAbsolute lymphocyte count <500.

^fIncludes 4 patients with non-COVID viral infection and 4 patients with fungal infection.

^gPatients who had received both HSCT and CAR were classified as HSCT or CAR based on the last anti-cancer therapy prior to COVID-19 infection.